{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,22]],"date-time":"2026-01-22T20:27:27Z","timestamp":1769113647386,"version":"3.49.0"},"reference-count":36,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2018,6,1]],"date-time":"2018-06-01T00:00:00Z","timestamp":1527811200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2018,6,1]],"date-time":"2018-06-01T00:00:00Z","timestamp":1527811200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2018,4,27]],"date-time":"2018-04-27T00:00:00Z","timestamp":1524787200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100003495","name":"Hessen State Ministry of Higher Education, Research and the Arts","doi-asserted-by":"publisher","award":["III L 4-518\/17.004 [2013]"],"award-info":[{"award-number":["III L 4-518\/17.004 [2013]"]}],"id":[{"id":"10.13039\/501100003495","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003042","name":"Else Kr\u00f6ner-Fresenius-Stiftung","doi-asserted-by":"publisher","award":["P75\/08\/\/A62\/08"],"award-info":[{"award-number":["P75\/08\/\/A62\/08"]}],"id":[{"id":"10.13039\/501100003042","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003042","name":"Else Kr\u00f6ner-Fresenius-Stiftung","doi-asserted-by":"publisher","award":["2014_A305"],"award-info":[{"award-number":["2014_A305"]}],"id":[{"id":"10.13039\/501100003042","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["celltherapyjournal.org","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Cytotherapy"],"published-print":{"date-parts":[[2018,6]]},"DOI":"10.1016\/j.jcyt.2018.04.005","type":"journal-article","created":{"date-parts":[[2018,5,10]],"date-time":"2018-05-10T08:38:12Z","timestamp":1525941492000},"page":"839-850","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":10,"title":["Epstein-Barr virus\u2013specific cytokine-induced killer cells for treatment of Epstein-Barr virus\u2013related malignant lymphoma"],"prefix":"10.1016","volume":"20","author":[{"given":"Lisa-Marie","family":"Pfeffermann","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Verena","family":"Pfirrmann","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sabine","family":"Huenecke","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Melanie","family":"Bremm","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Halvard","family":"Bonig","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hans-Michael","family":"Kvasnicka","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Thomas","family":"Klingebiel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Peter","family":"Bader","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eva","family":"Rettinger","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.jcyt.2018.04.005_bib0010","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1038\/bmt.2013.96","article-title":"EBV-induced post transplant lymphoproliferative disorders: a persisting challenge in allogeneic hematopoetic SCT","volume":"49","author":"Rasche","year":"2014","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.jcyt.2018.04.005_bib0015","doi-asserted-by":"crossref","first-page":"3654","DOI":"10.1182\/blood.V91.10.3654","article-title":"Semiquantitative Epstein-Barr virus (EBV) polymerase chain reaction for the determination of patients at risk for EBV-induced lymphoproliferative disease after stem cell transplantation","volume":"91","author":"Lucas","year":"1998","journal-title":"Blood"},{"key":"10.1016\/j.jcyt.2018.04.005_bib0020","first-page":"2208","article-title":"Risk of lymphoproliferative disorders after bone marrow transplantation: a multi-institutional study","volume":"94","author":"Curtis","year":"1999","journal-title":"Blood"},{"key":"10.1016\/j.jcyt.2018.04.005_bib0025","doi-asserted-by":"crossref","first-page":"972","DOI":"10.1182\/blood.V98.4.972","article-title":"Epstein-Barr virus (EBV) reactivation is a frequent event after allogeneic stem cell transplantation (SCT) and quantitatively predicts EBV-lymphoproliferative disease following T-cell\u2013depleted SCT","volume":"98","author":"van Esser","year":"2001","journal-title":"Blood"},{"key":"10.1016\/j.jcyt.2018.04.005_bib0030","doi-asserted-by":"crossref","first-page":"520","DOI":"10.1182\/blood.V72.2.520.520","article-title":"Epstein-Barr virus lymphoproliferation after bone marrow transplantation","volume":"72","author":"Zutter","year":"1988","journal-title":"Blood"},{"key":"10.1016\/j.jcyt.2018.04.005_bib0035","doi-asserted-by":"crossref","first-page":"981","DOI":"10.1038\/sj.bmt.1701468","article-title":"Lymphoproliferative disorders following allogeneic bone marrow transplantation: the Vancouver experience","volume":"22","author":"Micallef","year":"1998","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.jcyt.2018.04.005_bib0040","doi-asserted-by":"crossref","first-page":"794","DOI":"10.1093\/cid\/cit391","volume":"57","author":"Styczynski","year":"2013","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.jcyt.2018.04.005_bib0045","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1146\/annurev.micro.54.1.19","article-title":"Role of cytotoxic T lymphocytes in Epstein-Barr virus-associated diseases","volume":"54","author":"Khanna","year":"2000","journal-title":"Annu Rev Microbiol"},{"key":"10.1016\/j.jcyt.2018.04.005_bib0050","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1056\/NEJM200008173430707","article-title":"Epstein-Barr virus infection","volume":"343","author":"Cohen","year":"2000","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jcyt.2018.04.005_bib0055","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1146\/annurev.med.56.082103.104727","article-title":"Post-transplant lymphoproliferative disorders","volume":"56","author":"Gottschalk","year":"2005","journal-title":"Annu Rev Med"},{"key":"10.1016\/j.jcyt.2018.04.005_bib0060","doi-asserted-by":"crossref","first-page":"1648","DOI":"10.1111\/j.1600-6143.2007.01823.x","article-title":"Preemptive therapy of EBV-related lymphoproliferative disease after pediatric haploidentical stem cell transplantation","volume":"7","author":"Comoli","year":"2007","journal-title":"Am J Transplant"},{"key":"10.1016\/j.jcyt.2018.04.005_bib0065","doi-asserted-by":"crossref","first-page":"4364","DOI":"10.1182\/blood.V99.12.4364","article-title":"Prevention of Epstein-Barr virus-lymphoproliferative disease by molecular monitoring and preemptive rituximab in high-risk patients after allogeneic stem cell transplantation","volume":"99","author":"van Esser","year":"2002","journal-title":"Blood"},{"key":"10.1016\/j.jcyt.2018.04.005_bib0070","doi-asserted-by":"crossref","first-page":"4002","DOI":"10.1182\/blood-2009-07-143545","article-title":"How I treat EBV lymphoproliferation","volume":"114","author":"Heslop","year":"2009","journal-title":"Blood"},{"key":"10.1016\/j.jcyt.2018.04.005_bib0075","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1038\/sj.bmt.1701554","article-title":"B cell lymphoproliferative disorders following hematopoietic stem cell transplantation: risk factors, treatment and outcome","volume":"23","author":"Gross","year":"1999","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.jcyt.2018.04.005_bib0080","doi-asserted-by":"crossref","first-page":"1185","DOI":"10.1056\/NEJM199404283301703","article-title":"Infusions of donor leukocytes to treat Epstein-Barr virus-associated lymphoproliferative disorders after allogeneic bone marrow transplantation","volume":"330","author":"Papadopoulos","year":"1994","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jcyt.2018.04.005_bib0085","doi-asserted-by":"crossref","first-page":"e189","DOI":"10.1542\/peds.2011-0636","article-title":"Unmanipulated donor lymphocytes for EBV-related PTLD after T-cell depleted HLA-haploidentical transplantation","volume":"129","author":"De Pasquale","year":"2012","journal-title":"Pediatrics"},{"key":"10.1016\/j.jcyt.2018.04.005_bib0090","doi-asserted-by":"crossref","first-page":"1549","DOI":"10.1182\/blood.V92.5.1549.417k32_1549_1555","article-title":"Infusion of cytotoxic T cells for the prevention and treatment of Epstein-Barr virus-induced lymphoma in allogeneic transplant recipients","volume":"92","author":"Rooney","year":"1998","journal-title":"Blood"},{"key":"10.1016\/j.jcyt.2018.04.005_bib0095","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1016\/j.jcyt.2013.11.010","article-title":"The time is now: moving toward virus-specific T cells after allogeneic hematopoietic stem cell transplantation as the standard of care","volume":"16","author":"Saglio","year":"2014","journal-title":"Cytotherapy"},{"key":"10.1016\/j.jcyt.2018.04.005_bib0100","doi-asserted-by":"crossref","first-page":"841","DOI":"10.1093\/intimm\/dxn042","article-title":"Alloreactivity and anti-tumor activity segregate within two distinct subsets of cytokine-induced killer (CIK) cells: implications for their infusion across major HLA barriers","volume":"20","author":"Sangiolo","year":"2008","journal-title":"Int Immunol"},{"key":"10.1016\/j.jcyt.2018.04.005_bib0105","doi-asserted-by":"crossref","first-page":"3301","DOI":"10.1182\/blood-2011-02-336321","article-title":"Dual-functional capability of CD3+CD56+ CIK cells, a T-cell subset that acquires NK function and retains TCR-mediated specific cytotoxicity","volume":"118","author":"Pievani","year":"2011","journal-title":"Blood"},{"key":"10.1016\/j.jcyt.2018.04.005_bib0110","doi-asserted-by":"crossref","first-page":"91","DOI":"10.3109\/14653249.2011.613931","article-title":"The cytotoxic potential of interleukin-15-stimulated cytokine-induced killer cells against leukemia cells","volume":"14","author":"Rettinger","year":"2012","journal-title":"Cytotherapy"},{"key":"10.1016\/j.jcyt.2018.04.005_bib0115","doi-asserted-by":"crossref","first-page":"e153","DOI":"10.3324\/haematol.2015.138016","article-title":"Interleukin-15-activated cytokine-induced killer cells may sustain remission in leukemia patients after allogeneic stem cell transplantation: feasibility, safety and first insights on efficacy","volume":"101","author":"Rettinger","year":"2016","journal-title":"Haematologica"},{"key":"10.1016\/j.jcyt.2018.04.005_bib0120","doi-asserted-by":"crossref","first-page":"957","DOI":"10.1038\/bmt.2011.202","article-title":"The anti-tumour activity of allogeneic cytokine-induced killer cells in patients who relapse after allogeneic transplant for haematological malignancies","volume":"47","author":"Linn","year":"2012","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.jcyt.2018.04.005_bib0125","doi-asserted-by":"crossref","first-page":"1679","DOI":"10.1016\/j.bbmt.2011.05.012","article-title":"Adoptive immunotherapy with cytokine-induced killer cells for patients with relapsed hematologic malignancies after allogeneic hematopoietic cell\u00a0transplantation","volume":"17","author":"Laport","year":"2011","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.jcyt.2018.04.005_bib0130","doi-asserted-by":"crossref","first-page":"952","DOI":"10.3324\/haematol.11132","article-title":"Repeated infusions of donor-derived cytokine-induced killer cells in patients relapsing after allogeneic stem cell transplantation: a phase I study","volume":"92","author":"Introna","year":"2007","journal-title":"Haematologica"},{"key":"10.1016\/j.jcyt.2018.04.005_bib0135","doi-asserted-by":"crossref","first-page":"1139","DOI":"10.1016\/j.jcyt.2015.04.011","article-title":"Cytomegalovirus-specific cytokine-induced killer cells: concurrent targeting of leukemia and cytomegalovirus","volume":"17","author":"Pfirrmann","year":"2015","journal-title":"Cytotherapy"},{"key":"10.1016\/j.jcyt.2018.04.005_bib0140","doi-asserted-by":"crossref","first-page":"1141","DOI":"10.1038\/bmt.2013.19","article-title":"Feasibility of IL-15-activated cytokine-induced killer cell infusions after haploidentical stem cell transplantation","volume":"48","author":"Rettinger","year":"2013","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.jcyt.2018.04.005_bib0145","doi-asserted-by":"crossref","first-page":"2049","DOI":"10.1038\/nprot.2007.296","article-title":"Monitoring lymphocyte proliferation in vitro and in vivo with the intracellular fluorescent dye carboxyfluorescein diacetate succinimidyl ester","volume":"2","author":"Quah","year":"2007","journal-title":"Nat Protoc"},{"key":"10.1016\/j.jcyt.2018.04.005_bib0150","doi-asserted-by":"crossref","first-page":"835","DOI":"10.1016\/j.jcyt.2014.01.003","article-title":"Immunomagnetic selection or irradiation eliminates alloreactive cells but also reduces anti-tumor potential of cytokine-induced killer cells: implications for unmanipulated cytokine-induced killer cell infusion","volume":"16","author":"Rettinger","year":"2014","journal-title":"Cytotherapy"},{"key":"10.1016\/j.jcyt.2018.04.005_bib0155","doi-asserted-by":"crossref","first-page":"1603","DOI":"10.1016\/j.bbmt.2010.05.015","article-title":"Feasibility and safety of adoptive immunotherapy with CIK cells after cord blood transplantation","volume":"16","author":"Introna","year":"2010","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.jcyt.2018.04.005_bib0160","doi-asserted-by":"crossref","first-page":"1160","DOI":"10.1038\/nm1475","article-title":"Monoculture-derived T lymphocytes specific for multiple viruses expand and produce clinically relevant effects in immunocompromised individuals","volume":"12","author":"Leen","year":"2006","journal-title":"Nat Med"},{"key":"10.1016\/j.jcyt.2018.04.005_bib0165","doi-asserted-by":"crossref","first-page":"925","DOI":"10.1182\/blood-2009-08-239186","article-title":"Long-term outcome of EBV-specific T-cell infusions to prevent or treat EBV-related lymphoproliferative disease in transplant recipients","volume":"115","author":"Heslop","year":"2010","journal-title":"Blood"},{"key":"10.1016\/j.jcyt.2018.04.005_bib0170","doi-asserted-by":"crossref","first-page":"2838","DOI":"10.1182\/blood-2007-05-091280","article-title":"Complete responses of relapsed lymphoma following genetic modification of tumor-antigen presenting cells and T-lymphocyte transfer","volume":"110","author":"Bollard","year":"2007","journal-title":"Blood"},{"key":"10.1016\/j.jcyt.2018.04.005_bib0175","doi-asserted-by":"crossref","first-page":"1623","DOI":"10.1084\/jem.20040890","article-title":"Cytotoxic T lymphocyte therapy for Epstein-Barr virus+ Hodgkin's disease","volume":"200","author":"Bollard","year":"2004","journal-title":"J Exp Med"},{"key":"10.1016\/j.jcyt.2018.04.005_bib0180","doi-asserted-by":"crossref","first-page":"2942","DOI":"10.1182\/blood-2006-05-021782","article-title":"Treatment of solid organ transplant recipients with autologous Epstein Barr virus-specific cytotoxic T lymphocytes (CTLs)","volume":"108","author":"Savoldo","year":"2006","journal-title":"Blood"},{"key":"10.1016\/j.jcyt.2018.04.005_bib0185","first-page":"12","article-title":"Donor mononuclear cell infusions as therapy for B-cell lymphoproliferative disorder following allogeneic bone marrow transplant","volume":"4","author":"Porter","year":"1994","journal-title":"Transplant Sci"}],"container-title":["Cytotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1465324918305097?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1465324918305097?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,26]],"date-time":"2025-10-26T01:35:44Z","timestamp":1761442544000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1465324918305097"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,6]]},"references-count":36,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2018,6]]}},"alternative-id":["S1465324918305097"],"URL":"https:\/\/doi.org\/10.1016\/j.jcyt.2018.04.005","relation":{},"ISSN":["1465-3249"],"issn-type":[{"value":"1465-3249","type":"print"}],"subject":[],"published":{"date-parts":[[2018,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Epstein-Barr virus\u2013specific cytokine-induced killer cells for treatment of Epstein-Barr virus\u2013related malignant lymphoma","name":"articletitle","label":"Article Title"},{"value":"Cytotherapy","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jcyt.2018.04.005","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 International Society for Cellular Therapy. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}